FUNDAMENTALS · Fundamentals · AU Healthcare

Avecho Biotechnology (AVE) Fundamentals 2026 — Revenue Analysis | SniperIQ

Avecho Biotechnology (AVE) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$65M, trading at A$0.02 on the ASX. This SniperIQ fundamentals page covers Avecho Biotechnology's valuation, profitability (net margin -248.7%), revenue (A

M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA$65M
Net Margin-248.7%
Revenue (FY25)A
M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Avecho Biotechnology's market cap?

Avecho Biotechnology (AVE) has a market capitalization of approximately A$65M, trading at A$0.02 on the ASX. Market cap moves with the live share price.

What is Avecho Biotechnology's P/E ratio?

Avecho Biotechnology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 48.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Avecho Biotechnology?

Avecho Biotechnology runs a net profit margin of -248.7%, a gross margin of 60.7%, and an operating margin of -485.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Avecho Biotechnology generate?

Avecho Biotechnology reported revenue of A

M for fiscal year 2025, with net income of -A$4M and earnings per share (EPS) of -0.0014. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Avecho Biotechnology pay a dividend?

Avecho Biotechnology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Avecho Biotechnology financially healthy?

Avecho Biotechnology carries a debt-to-equity ratio of 0.01x and a current ratio of 9.95x, with a market beta of 1.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Avecho Biotechnology a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Avecho Biotechnology (AVE) the key facts are: market cap A$65M, revenue A

M, 52-week range 0.004-0.027. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Avecho Biotechnology's full fundamentals live

Get Avecho Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: CAMP4 Therapeutics (CAMP) fundamentals · Singular Health Group (SHG) fundamentals · Pliant Therapeutics (PLRX) fundamentals · Tiziana Life Sciences (TLSA) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons